Lecia V Sequist
Lecia V Sequist
Professor of Medicine, Harvard Medical School and Massachusetts General Hospital
Verified email at
Cited by
Cited by
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
Isolation of rare circulating tumour cells in cancer patients by microchip technology
S Nagrath, LV Sequist, S Maheswaran, DW Bell, D Irimia, L Ulkus, ...
Nature 450 (7173), 1235-1239, 2007
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ...
Journal of clinical oncology 31 (27), 3327-3334, 2013
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ...
Science translational medicine 3 (75), 75ra26-75ra26, 2011
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
M Yu, A Bardia, BS Wittner, SL Stott, ME Smas, DT Ting, SJ Isakoff, ...
science 339 (6119), 580-584, 2013
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
S Maheswaran, LV Sequist, S Nagrath, L Ulkus, B Brannigan, CV Collura, ...
New England Journal of Medicine 359 (4), 366-377, 2008
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
SL Stott, CH Hsu, DI Tsukrov, M Yu, DT Miyamoto, BA Waltman, ...
Proceedings of the National Academy of Sciences 107 (43), 18392-18397, 2010
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ...
Jama 311 (19), 1998-2006, 2014
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ...
The lancet oncology 17 (11), 1497-1508, 2016
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ...
Science translational medicine 4 (120), 120ra17-120ra17, 2012
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004, 2015
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ...
Cancer cell 17 (1), 77-88, 2010
Inertial focusing for tumor antigen–dependent and–independent sorting of rare circulating tumor cells
E Ozkumur, AM Shah, JC Ciciliano, BL Emmink, DT Miyamoto, E Brachtel, ...
Science translational medicine 5 (179), 179ra47-179ra47, 2013
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective …
JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ...
Clinical cancer research 22 (18), 4585-4593, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
LV Sequist, RG Martins, D Spigel, SM Grunberg, A Spira, PA Janne, ...
Journal of clinical oncology 26 (15), 2442-2449, 2008
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ...
Nature medicine 22 (3), 262-269, 2016
Acquired resistance to TKIs in solid tumours: learning from lung cancer
DR Camidge, W Pao, LV Sequist
Nature reviews Clinical oncology 11 (8), 473-481, 2014
The system can't perform the operation now. Try again later.
Articles 1–20